Product Code: GVR-4-68040-136-5
Multiomics Market Growth & Trends:
The global multiomics market size is expected to reach USD 6.38 billion by 2030, registering a CAGR of 15.3% from 2023 to 2030, according to a new report by Grand View Research, Inc.. Factors such as the decreasing costs of omics technologies and growing investment and funding from private and public players are expected to drive the market. In addition, rising competition in the market owing to increasing demand from pharmaceutical & biotechnology companies and academic research institutions is also anticipated to propel the market growth over the forecast period.
With the improvement in technologies, the cost of omics technologies is anticipated to reduce, which can increase the accessibility of datasets to researchers, consequently driving market growth. Companies are focusing on technological advancements to lower costs. For instance, in November 2022, Amazon Web Services introduced an Amazon Omics service. This service utilizes bioinformatics-aware storage options to store raw sequence data and to decrease costs. Thus, the decreasing costs are anticipated to increase the accessibility of omics technologies to researchers and clinicians. Such cost reduction is expected to increase the adoption of multiomics approaches.
The growing investments and funding from private and public participants are anticipated to boost the demand for multi-omics products and services. Various companies are significantly investing in the development of multiomics platforms and technologies. For instance, in January 2022, Roche invested USD 290 million in Freenome, a biotech company. This investment was used to accelerate multiomics platforms for early cancer detection. In addition, in May 2023, MultiOmic Health completed a funding round of USD 6.2 million to construct a precision therapeutics discovery platform. Thus, the rising funding and investments are expected to develop various novel platforms and products in the markets
The rising emphasis of market players to develop innovative products and services is another vital factor propelling market demand forward. Various companies are developing novel platforms to sustain the rising competition. For instance, in February 2023, Via Scientific, Inc. introduced a multi-omics accelerator platform, Foundry, that supports the automation of complex data and analytical work during multi-omics research. Such product launches are anticipated to drive the industry over the forecast period.
Multiomics Market Report Highlights:
- Based on product & service, the product segment dominated the market with a revenue share of 60.5% in 2022, which can be attributed to the rising launches of products such as instruments and software
- Based on type, the bulk multiomics held the largest revenue contributor for the industry. In contrast, single-cell multi-omics is expected to grow at the fastest CAGR of 17.8% over the forecast period, due to increasing demand for single-cell multi-omics to comprehend complex biology systems
- Based on platform, genomics dominated the market with a revenue share of 40.6% in 2022. The growth is attributed to the high number of products available in this segment
- Based on application, the cell biology segment dominated the global industry with a share of 38.8% in 2022. In contrast, the oncology segment is projected to register the highest growth rate during the projected period
- Based on end-use, the academic and research institute segment was the largest revenue contributor for the industry, with a share of 50.7%. In contrast, pharmaceutical and biotechnology companies are expected to witness the fastest growth owing to increasing demand for multi-omics to accelerate drug discovery and development
- North America dominated the global industry in 2022 with a revenue share of 48.45%, owing to the presence of key market players in the region
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Market Definitions
- 1.2.1. Information Analysis
- 1.2.2. Market Platform & Data Visualization
- 1.2.3. Data Validation & Publishing
- 1.3. Research Assumptions
- 1.4. Information Procurement
- 1.5. Information or Data Analysis
- 1.6. Market Platform & Validation
- 1.7. Market Model
- 1.8. Global Market: CAGR Calculation
- 1.9. Objectives
- 1.9.1. Objective 1
- 1.9.2. Objective 2
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Increasing demand for single cell omics
- 3.2.1.2. Advancements in omics technology and decreasing costs of omics technologies
- 3.2.1.3. Increasing investments and funding from private and public players
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. Challenges in multiomics data integration and data complexity
- 3.3. Industry Analysis Tools
- 3.3.1. Porter's Five Forces Analysis
- 3.3.2. PESTEL Analysis
- 3.3.3. COVID-19 Impact Analysis
Chapter 4. Product & Service Business Analysis
- 4.1. Multiomics Market: Product & Service Movement Analysis
- 4.2. Products
- 4.2.1. Products Market, 2018 - 2030 (USD Million)
- 4.2.2. Instruments
- 4.2.2.1. Instruments Market, 2018 - 2030 (USD Million)
- 4.2.3. Consumables
- 4.2.3.1. Consumables Market, 2018 - 2030 (USD Million)
- 4.2.4. Software
- 4.2.4.1. Software Market, 2018 - 2030 (USD Million)
- 4.3. Services
- 4.3.1. Services Market, 2018 - 2030 (USD Million)
Chapter 5. Type Business Analysis
- 5.1. Multiomics Market: Type Movement Analysis
- 5.2. Single- Cell Multiomics
- 5.2.1. Single- Cell Multiomics Market, 2018 - 2030 (USD Million)
- 5.3. Bulk Multiomics
- 5.3.1. Bulk Multiomics Market, 2018 - 2030 (USD Million)
Chapter 6. Platform Business Analysis
- 6.1. Multiomics Market: Platform Movement Analysis
- 6.2. Genomics
- 6.2.1. Genomics Market, 2018 - 2030 (USD Million)
- 6.3. Transcriptomics
- 6.3.1. Transcriptomics Market, 2018 - 2030 (USD Million)
- 6.4. Proteomics
- 6.4.1. Proteomics Market, 2018 - 2030 (USD Million)
- 6.5. Metabolomics
- 6.5.1. Metabolomics Market, 2018 - 2030 (USD Million)
- 6.6. Integrated Omics Platforms
- 6.6.1. Integrated Omics Platforms Market, 2018 - 2030 (USD Million)
Chapter 7. Application Business Analysis
- 7.1. Multiomics Market: Application Movement Analysis
- 7.2. Cell Biology
- 7.2.1. Cell Biology Market, 2018 - 2030 (USD Million)
- 7.3. Oncology
- 7.3.1. Oncology Market, 2018 - 2030 (USD Million)
- 7.4. Neurology
- 7.4.1. Neurology Market, 2018 - 2030 (USD Million)
- 7.5. Immunology
- 7.5.1. Immunology Market, 2018 - 2030 (USD Million)
Chapter 8. End-use Business Analysis
- 8.1. Multiomics Market: End-use Movement Analysis
- 8.2. Academic and Research Institutes
- 8.2.1. Academic and Research Institutes Market, 2018 - 2030 (USD Million)
- 8.3. Pharmaceutical & Biotechnology Companies
- 8.3.1. Pharmaceutical & Biotechnology Companies Market, 2018 - 2030 (USD Million)
- 8.4. Others
- 8.4.1. Others Market, 2018 - 2030 (USD Million)
Chapter 9. Regional Business Analysis
- 9.1. Multiomics Market Share By Region, 2022 & 2030
- 9.2. North America
- 9.2.1. North America Multiomics Market, 2018 - 2030 (USD Million)
- 9.2.2. U.S.
- 9.2.2.1. Key Country Dynamics
- 9.2.2.2. Target Disease Prevalence
- 9.2.2.3. Competitive Scenario
- 9.2.2.4. U.S. Multiomics Market, 2018 - 2030 (USD Million)
- 9.2.3. Canada
- 9.2.3.1. Key Country Dynamics
- 9.2.3.2. Target Disease Prevalence
- 9.2.3.3. Competitive Scenario
- 9.2.3.4. Canada Multiomics Market, 2018 - 2030 (USD Million)
- 9.3. Europe
- 9.3.1. Europe Multiomics Market, 2018 - 2030 (USD Million)
- 9.3.2. UK
- 9.3.2.1. Key Country Dynamics
- 9.3.2.2. Target Disease Prevalence
- 9.3.2.3. Competitive Scenario
- 9.3.2.4. UK Multiomics Market, 2018 - 2030 (USD Million)
- 9.3.3. Germany
- 9.3.3.1. Key Country Dynamics
- 9.3.3.2. Target Disease Prevalence
- 9.3.3.3. Competitive Scenario
- 9.3.3.4. Germany Multiomics Market, 2018 - 2030 (USD Million)
- 9.3.4. France
- 9.3.4.1. Key Country Dynamics
- 9.3.4.2. Target Disease Prevalence
- 9.3.4.3. Competitive Scenario
- 9.3.4.4. France Multiomics Market, 2018 - 2030 (USD Million)
- 9.3.5. Italy
- 9.3.5.1. Key Country Dynamics
- 9.3.5.2. Target Disease Prevalence
- 9.3.5.3. Competitive Scenario
- 9.3.5.4. Italy Multiomics Market, 2018 - 2030 (USD Million)
- 9.3.6. Spain
- 9.3.6.1. Key Country Dynamics
- 9.3.6.2. Target Disease Prevalence
- 9.3.6.3. Competitive Scenario
- 9.3.6.4. Spain Multiomics Market, 2018 - 2030 (USD Million)
- 9.3.7. Denmark
- 9.3.7.1. Key Country Dynamics
- 9.3.7.2. Target Disease Prevalence
- 9.3.7.3. Competitive Scenario
- 9.3.7.4. Denmark Multiomics Market, 2018 - 2030 (USD Million)
- 9.3.8. Sweden
- 9.3.8.1. Key Country Dynamics
- 9.3.8.2. Target Disease Prevalence
- 9.3.8.3. Competitive Scenario
- 9.3.8.4. Sweden Multiomics Market, 2018 - 2030 (USD Million)
- 9.3.9. Norway
- 9.3.9.1. Key Country Dynamics
- 9.3.9.2. Target Disease Prevalence
- 9.3.9.3. Competitive Scenario
- 9.3.9.4. Norway Multiomics Market, 2018 - 2030 (USD Million)
- 9.4. Asia Pacific
- 9.4.1. Asia Pacific Multiomics Market, 2018 - 2030 (USD Million)
- 9.4.2. Japan
- 9.4.2.1. Key Country Dynamics
- 9.4.2.2. Target Disease Prevalence
- 9.4.2.3. Competitive Scenario
- 9.4.2.4. Japan Multiomics Market, 2018 - 2030 (USD Million)
- 9.4.3. China
- 9.4.3.1. Key Country Dynamics
- 9.4.3.2. Target Disease Prevalence
- 9.4.3.3. Competitive Scenario
- 9.4.3.4. China Multiomics Market, 2018 - 2030 (USD Million)
- 9.4.4. India
- 9.4.4.1. Key Country Dynamics
- 9.4.4.2. Target Disease Prevalence
- 9.4.4.3. Competitive Scenario
- 9.4.4.4. India Multiomics Market, 2018 - 2030 (USD Million)
- 9.4.5. Australia
- 9.4.5.1. Key Country Dynamics
- 9.4.5.2. Target Disease Prevalence
- 9.4.5.3. Competitive Scenario
- 9.4.5.4. Australia Multiomics Market, 2018 - 2030 (USD Million)
- 9.4.6. Thailand
- 9.4.6.1. Key Country Dynamics
- 9.4.6.2. Target Disease Prevalence
- 9.4.6.3. Competitive Scenario
- 9.4.6.4. Thailand Multiomics Market, 2018 - 2030 (USD Million)
- 9.4.7. South Korea
- 9.4.7.1. Key Country Dynamics
- 9.4.7.2. Target Disease Prevalence
- 9.4.7.3. Competitive Scenario
- 9.4.7.4. South Korea Multiomics Market, 2018 - 2030 (USD Million)
- 9.5. Latin America
- 9.5.1. Latin America Multiomics Market, 2018 - 2030 (USD Million)
- 9.5.2. Brazil
- 9.5.2.1. Key Country Dynamics
- 9.5.2.2. Target Disease Prevalence
- 9.5.2.3. Competitive Scenario
- 9.5.2.4. Brazil Multiomics Market, 2018 - 2030 (USD Million)
- 9.5.3. Mexico
- 9.5.3.1. Key Country Dynamics
- 9.5.3.2. Target Disease Prevalence
- 9.5.3.3. Competitive Scenario
- 9.5.3.4. Mexico Multiomics Market, 2018 - 2030 (USD Million)
- 9.5.4. Argentina
- 9.5.4.1. Key Country Dynamics
- 9.5.4.2. Target Disease Prevalence
- 9.5.4.3. Competitive Scenario
- 9.5.4.4. Argentina Multiomics Market, 2018 - 2030 (USD Million)
- 9.6. MEA
- 9.6.1. MEA Multiomics Market, 2018 - 2030 (USD Million)
- 9.6.2. South Africa
- 9.6.2.1. Key Country Dynamics
- 9.6.2.2. Target Disease Prevalence
- 9.6.2.3. Competitive Scenario
- 9.6.2.4. South Africa Multiomics Market, 2018 - 2030 (USD Million)
- 9.6.3. Saudi Arabia
- 9.6.3.1. Key Country Dynamics
- 9.6.3.2. Target Disease Prevalence
- 9.6.3.3. Competitive Scenario
- 9.6.3.4. Saudi Arabia Multiomics Market, 2018 - 2030 (USD Million)
- 9.6.4. UAE
- 9.6.4.1. Key Country Dynamics
- 9.6.4.2. Target Disease Prevalence
- 9.6.4.3. Competitive Scenario
- 9.6.4.4. UAE Multiomics Market, 2018 - 2030 (USD Million)
- 9.6.5. Kuwait
- 9.6.5.1. Key Country Dynamics
- 9.6.5.2. Target Disease Prevalence
- 9.6.5.3. Competitive Scenario
- 9.6.5.4. Kuwait Multiomics Market, 2018 - 2030 (USD Million)
Chapter 10. Competitive Landscape
- 10.1. Company Categorization
- 10.2. Strategy Mapping
- 10.3. Company Market Position Analysis, 2022
- 10.4. Company Profiles/Listing
- 10.4.1. BD
- 10.4.1.1. Overview
- 10.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 10.4.1.3. Product Benchmarking
- 10.4.1.4. Strategic Initiatives
- 10.4.2. Thermo Fisher Scientific, Inc,
- 10.4.2.1. Overview
- 10.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 10.4.2.3. Product Benchmarking
- 10.4.2.4. Strategic Initiatives
- 10.4.3. Illumina
- 10.4.3.1. Overview
- 10.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 10.4.3.3. Product Benchmarking
- 10.4.3.4. Strategic Initiatives
- 10.4.4. Danaher
- 10.4.4.1. Overview
- 10.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 10.4.4.3. Product Benchmarking
- 10.4.4.4. Strategic Initiatives
- 10.4.5. PerkinElmer
- 10.4.5.1. Overview
- 10.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 10.4.5.3. Product Benchmarking
- 10.4.5.4. Strategic Initiatives
- 10.4.6. Shimadzu Corporation
- 10.4.6.1. Overview
- 10.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 10.4.6.3. Product Benchmarking
- 10.4.6.4. Strategic Initiatives
- 10.4.7. Bruker
- 10.4.7.1. Overview
- 10.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 10.4.7.3. Product Benchmarking
- 10.4.7.4. Strategic Initiatives
- 10.4.8. QIAGEN
- 10.4.8.1. Overview
- 10.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 10.4.8.3. Product Benchmarking
- 10.4.8.4. Strategic Initiatives
- 10.4.9. Agilent Technologies
- 10.4.9.1. Overview
- 10.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 10.4.9.3. Product Benchmarking
- 10.4.9.4. Strategic Initiatives
- 10.4.10. BGI
- 10.4.10.1. Overview
- 10.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 10.4.10.3. Product Benchmarking
- 10.4.10.4. Strategic Initiatives